4D Molecular Therapeutics, Inc. (FDMT)
Develops gene therapy treatments using modified viruses to treat eye and lung diseases.
$9.82-0.05%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+52.9%
The outlook
FDMT is trading near the middle of its 52-week range with analyst consensus firmly at "Buy." The average price target sits roughly 188% above the current price, though the stock shows mixed momentum against its moving averages. Overall sentiment leans bullish based on available data.
What’s behind the score
Analyst consensusBuy — 1.5 avg of 9 analysts
Price trendMixed vs its moving averages
52-week range57% of the way from its 52-week low to high
Price targetAvg target +188% vs current price
Analyst price target
~12-month · 9 analysts$28.22average target+187.5% vs now
Now $9.82
Low $17.00High $36.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$513.1M
52-wk high
$14.00
52-wk low
$4.27
50-day avg
$10.39
200-day avg
$9.76
Trailing P/E
—